U.S. flag

An official website of the United States government

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.

Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization; 2014 Dec.

Cover
  • This publication is provided for historical reference only and the information may be out of date.

This publication is provided for historical reference only and the information may be out of date.

Cover of Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach

Guidelines on Post-Exposure Prophylaxis for HIV and the Use of Co-Trimoxazole Prophylaxis for HIV-Related Infections Among Adults, Adolescents and Children: Recommendations for a Public Health Approach: December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection.

Show details

REFERENCES

    SECTION 1. INTRODUCTION

    1.
    Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/arv2013/download/en. [PubMed: 24716260]
    2.
    Post-exposure prophylaxis to prevent HIV infection: joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. Geneva: World Health Organization; 2007. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/post-exposureprophylaxis/en.
    3.
    Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva: World Health Organization; 2006. [18 November 2014]. http://www​.who.int/hiv/pub/plhiv/ctx/en. [PubMed: 26042326]

    SECTION 2. METHODS

    1.
    Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924–6. [PMC free article: PMC2335261] [PubMed: 18436948]
    2.
    Andrews JC, Schünemann HJ, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation – determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66:726–35. [PubMed: 23570745]
    3.
    Balshem H, Helfand M, Schünemann HJ, Oxman AD, Kunz R, Brozek J, et al. GRADE guidelines. 3. Rating the quality of evidence. J Clin Epidemiol. 2011;64:401–6. [PubMed: 21208779]
    4.
    GRADE Working Group [website]. GRADE Working Group; 2014. [18 November 2014]. www​.gradeworkinggroup.org.
    5.
    WHO handbook for guideline development. Geneva: World Health Organization; 2012. [18 November 2014]. http://apps​.who.int/iris​/bitstream/10665​/75146/1/9789241548441_eng.pdf.

    SECTION 3. GUIDING PRINCIPLES

    1.
    Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/arv2013/download/en. [PubMed: 24716260]

    SECTION 4. POST-EXPOSURE PROPHYLAXIS FOR HIV

    1.
    Post-exposure prophylaxis to prevent HIV infection: joint WHO/ILO guidelines on post-exposure prophylaxis (PEP) to prevent HIV infection. Geneva: World Health Organization; 2007. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/post-exposureprophylaxis/en.
    2.
    Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Geneva: World Health Organization; 2006. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/artadultguidelines.pdf.
    3.
    Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/arv2013/download/en. [PubMed: 24716260]
    4.
    Tsai CC, Follis KE, Sabo A, Beck TW, Grant RF, Bischofberger N, et al. Prevention of SIV infection in macaques by (R)-9-(2-phosphonylmethoxypropyl)adenine. Science. 1995;270:1197–9. [PubMed: 7502044]
    5.
    Cardo DM, Culver DH, Ciesielski CA, Srivastava PU, Marcus R, Abiteboul D, et al. A case–control study of HIV seroconversion in health care workers after percutaneous exposure. N Engl J Med. 1997;337:1485–90. [PubMed: 9366579]
    6.
    Young TN, Arens FJ, Kennedy GE, Laurie JW, Rutherford GW. Antiretroviral post-exposure prophylaxis (PEP) for occupational HIV exposure. Cochrane Database Syst Rev. 2007;(1) CD002835. [PMC free article: PMC8989146] [PubMed: 17253483]
    7.
    Bryant J, Baxter L, Hird S. Non-occupational postexposure prophylaxis for HIV: a systematic review. Health Technol Assess Winch Engl. 2009;13:iii, ix–x, 1–60. [PubMed: 19236820]
    8.
    Siegfried N, van der Merwe L, Brocklehurst P, Sint TT. Antiretrovirals for reducing the risk of mother-to-child transmission of HIV infection. Cochrane Database Syst Rev. 2011;(7) CD003510. [PubMed: 21735394]
    9.
    Okwundu CI, Uthman OA, Okoromah CA. Antiretroviral pre-exposure prophylaxis (PrEP) for preventing HIV in high-risk individuals. Cochrane Database Syst Rev. 2012;(7) CD007189. [PubMed: 22786505]
    10.
    Ford N, Shubber Z, Irvine C, Vitoria M, Doherty M. Poster presentation TUPE154 [Internet]. Melbourne, Australia: 2014. [18 November 2014]. Adherence to post exposure prophylaxis: where do losses occur? http://www​.aids2014.org​/webcontent/file/pag​/Posters/Tuesday/Tuesday.pdf.
    11.
    Ford N, Irvine C, Doherty M, Vitoria M, Baggaley R, Shubber Z. Poster presentation TUPE154. Melbourne, Australia: 2014. [18 November 2014]. Variation in adherence to post exposure prophylaxis by exposure type: a meta-analysis. http://www​.aids2014.org​/webcontent/file/pag​/Posters/Tuesday/Tuesday.pdf.
    12.
    Otten RA, Smith DK, Adams DR, Pullium JK, Jackson E, Kim CN, et al. Efficacy of postexposure prophylaxis after intravaginal exposure of pig-tailed macaques to a human-derived retrovirus (human immunodeficiency virus type 2). J Virol. 2000;74:9771–5. [PMC free article: PMC112413] [PubMed: 11000253]
    13.
    Tsai CC, Emau P, Follis KE, Beck TW, Benveniste RE, Bischofberger N, et al. Effectiveness of postinoculation (R)-9-(2-phosphonylmethoxypropyl) adenine treatment for prevention of persistent simian immunodeficiency virus SIVmne infection depends critically on timing of initiation and duration of treatment. J Virol. 1998;72:4265–73. [PMC free article: PMC109656] [PubMed: 9557716]
    14.
    Böttiger D, Johansson NG, Samuelsson B, Zhang H, Putkonen P, Vrang L, et al. Prevention of simian immunodeficiency virus, SIVsm, or HIV-2 infection in cynomolgus monkeys by pre-and postexposure administration of BEA-005. AIDS. 1997;11:157–62. [PubMed: 9030361]
    15.
    Martin LN, Murphey-Corb M, Soike KF, Davison-Fairburn B, Baskin GB. Effects of initiation of 3 -azido,3 -deoxythymidine (zidovudine) treatment at different times after infection of rhesus monkeys with simian immunodeficiency virus. J Infect Dis. 1993;168:825–35. [PubMed: 7690823]
    16.
    Patel P, Borkowf CB, Brooks JT, Lasry A, Lansky A, Mermin J. Estimating per-act HIV transmission risk: a systematic review. AIDS. 2014;28:1509–19. [PMC free article: PMC6195215] [PubMed: 24809629]
    17.
    Benn P, Fisher M, Kulasegaram R., on behalf of the BASHH, PEPSE Guidelines Writing Group Clinical Effectiveness Group. UK guideline for the use of post-exposure prophylaxis for HIV following sexual exposure (2011). Int J STD AIDS. 2011;22:695–708. [PubMed: 22174049]
    18.
    Kuhar DT, Henderson DK, Struble KA, Heneine W, Thomas V, Cheever LW, et al. Updated US Public Health Service guidelines for the management of occupational exposures to human immunodeficiency virus and recommendations for postexposure prophylaxis. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am. 2013;34:875–92. [PubMed: 23917901]
    19.
    Mayer KH, Mimiaga MJ, Cohen D, Grasso C, Bill R, VanDerwarker R, et al. Tenofovir DF plus lamivudine or emtricitabine for nonoccupational postexposure prophylaxis (NPEP) in a Boston Community Health Center. J Acquir Immune Defic Syndr. 2008;47:494–9. [PubMed: 18176318]
    20.
    Okulicz JF, Murray CK. Evaluation of HIV postexposure prophylaxis for occupational and nonoccupational exposures at a deployed U.S. military trauma hospital. Mil Med. 2012;177:1524–32. [PubMed: 23397700]
    21.
    Grime PR, Ris L, Binns C, Carruthers JR, Williams S. Pan-Thames survey of occupational exposure to HIV and the use of post-exposure prophylaxis in 71 NHS trusts. J Infect. 2001;42:27–32. [PubMed: 11243750]
    22.
    Wang SA, Panlilio AL, Doi PA, White AD, Stek M, Saah A. Experience of healthcare workers taking postexposure prophylaxis after occupational HIV exposures: findings of the HIV Postexposure Prophylaxis Registry. Infect Control Hosp Epidemiol. 2000;21:780–5. [PubMed: 11140914]
    23.
    Garcia-Lerma JG, Cong ME, Mitchell J, Youngpairoj AS, Zheng Q, Masciotra S, et al. Intermittent prophylaxis with oral Truvada protects macaques from rectal SHIV infection. Sci Transl Med. 2010;2:14ra4. [PubMed: 20371467]
    24.
    Campbell TB, Smeaton LM, Kumarasamy N, Flanigan T, Klingman KL, Firnhaber C, et al. Efficacy and safety of three antiretroviral regimens for initial treatment of HIV-1: a randomized clinical trial in diverse multinational settings. PLoS Med. 2012;9:e1001290. [PMC free article: PMC3419182] [PubMed: 22936892]
    25.
    Gallant JE, DeJesus E, Arribas JR, Pozniak AL, Gazzard B, Campo RE, et al. Tenofovir DF, emtricitabine, and efavirenz versus. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251–60. [PubMed: 16421366]
    26.
    Rey D, Hoen B, Chavanet P, Schmitt MP, Hoizey G, Meyer P, et al. High rate of early virological failure with the once-daily tenofovir/lamivudine/nevirapine combination in naive HIV-1-infected patients. J Antimicrob Chemother. 2008;63:380–8. [PubMed: 19036752]
    27.
    Baeten JM, Donnell D, Ndase P, Mugo NR, Campbell JD, Wangisi J, et al. Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. N Engl J Med. 2012;367:399–410. [PMC free article: PMC3770474] [PubMed: 22784037]
    28.
    Van Damme L, Corneli A, Ahmed K, Agot K, Lombaard J, Kapiga S, et al. Preexposure prophylaxis for HIV infection among African women. N Engl J Med. 2012;367:411–22. [PMC free article: PMC3687217] [PubMed: 22784040]
    29.
    Thigpen MC, Kebaabetswe PM, Paxton LA, Smith DK, Rose CE, Segolodi TM, et al. Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. N Engl J Med. 2012;367:423–34. [PubMed: 22784038]
    30.
    Grant RM, Lama JR, Anderson PL, McMahan V, Liu AY, Vargas L, et al. Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. N Engl J Med. 2010;363:2587–99. [PMC free article: PMC3079639] [PubMed: 21091279]
    31.
    Abrahams N, Jewkes R, Lombard C, Mathews S, Campbell J, Meel B. Impact of telephonic psycho-social support on adherence to post-exposure prophylaxis (PEP) after rape. AIDS Care. 2010;22:1173–81. [PubMed: 20640949]
    32.
    Garcia MT, Figueiredo RM, Moretti ML, Resende MR, Bedoni AJ, Papaiordanou PMO. Postexposure prophylaxis after sexual assaults: a prospective cohort study. Sex Transm Dis. 2005;32:214–9. [PubMed: 15788918]
    33.
    Kahn JO, Martin JN, Roland ME, Bamberger JD, Chesney M, Chambers D, et al. Feasibility of postexposure prophylaxis (PEP) against human immunodeficiency virus infection after sexual or injection drug use exposure: the San Francisco post-exposure prophylaxis Study. J Infect Dis. 2001;183:707–14. [PubMed: 11181146]
    34.
    Kim JC, Askew I, Muvhango L, Dwane N, Abramsky T, Jan S, et al. Comprehensive care and HIV prophylaxis after sexual assault in rural South Africa: the Refentse intervention study. BMJ. 2009;338:b515. [PubMed: 19286746]
    35.
    Neu N, Heffernan-Vacca S, Millery M, Stimell M, Brown J. Postexposure prophylaxis for HIV in children and adolescents after sexual assault: a prospective observational study in an urban medical center. Sex Transm Dis. 2007;34:65–8. [PubMed: 16794560]
    36.
    Roland ME, Neilands TB, Krone MR, Coates TJ, Franses K, Chesney MA, et al. A randomized noninferiority trial of standard versus enhanced risk reduction and adherence counseling for individuals receiving post-exposure prophylaxis following sexual exposures to HIV. Clin Infect Dis. 2011;53:76–83. [PMC free article: PMC3110285] [PubMed: 21653307]
    37.
    Schechter M, do Lago RF, Mendelsohn AB, Moreira RI, Moulton LH, Harrison LH, et al. Behavioral impact, acceptability, and HIV incidence among homosexual men with access to postexposure chemoprophylaxis for HIV. J Acquir Immune Defic Syndr. 2004;35:519–25. [PubMed: 15021317]
    38.
    Shoptaw S, Rotheram-Fuller E, Landovitz RJ, Wang J, Moe A, Kanouse DE, et al. Non-occupational post exposure prophylaxis as a biobehavioral HIV-prevention intervention. AIDS Care. 2008;20:376–81. [PubMed: 17963091]
    39.
    Speight CG, Klufio A, Kilonzo SN, Mbugua C, Kuria E, Bunn JE, et al. Piloting post-exposure prophylaxis in Kenya raises specific concerns for the management of childhood rape. Trans R Soc Trop Med Hyg. 2006;100:14–8. [PubMed: 16225898]
    40.
    Swotinsky RB, Steger KA, Sulis C, Snyder S, Craven DE. Occupational exposure to HIV: experience at a tertiary care center. J Occup Environ Med. 1998;40:1102–9. [PubMed: 9871887]
    41.
    Winston A, McAllister J, Amin J, Cooper DA, Carr A. The use of a triple nucleoside-nucleotide regimen for nonoccupational HIV post-exposure prophylaxis. HIV Med. 2005;6:191–7. [PubMed: 15876286]
    42.
    Landovitz RJ, Fletcher JB, Inzhakova G, Lake JE, Shoptaw S, Reback CJ. A novel combination HIV prevention strategy: post-exposure prophylaxis with contingency management for substance abuse treatment among methamphetamine-using men who have sex with men. AIDS Patient Care STDs. 2012;26:320–8. [PMC free article: PMC3366332] [PubMed: 22680280]
    43.
    McAllister J, Read P, McNulty A, Tong W, Ingersoll A, Carr A. Raltegravir-emtricitabine-tenofovir as HIV nonoccupational post-exposure prophylaxis in men who have sex with men: safety, tolerability and adherence: raltegravir-based NPEP in men who have sex with men. HIV Med. 2014;15:13–22. [PubMed: 24007390]
    44.
    Burty C, Pavel S, Ghomari K, Vermersch A, Christian B, Pouaha J, et al. Tolerability of fosamprenavir/ritonavir associated with zidovudine-lamivudine used as postexposure prophylaxis for HIV infection. J Acquir Immune Defic Syndr. 2008;49:334–6. [PubMed: 18978479]
    45.
    Diaz-Brito V, Lèon A, Knobel H, Peraire J, Domingo P, Clotet B, et al. Post-exposure prophylaxis for HIV infection: a clinical trial comparing lopinavir/ritonavir versus atazanavir each with zidovudine/lamivudine. Antivir Ther. 2012;17:337–46. [PubMed: 22293542]
    46.
    Fätkenheuer GJN, Jessen H, Stoehr A, Arasteh K, Bogner JR, Stephan C, et al. Darunavir(DRV)/r-based post-exposure prophylaxis versus standard of care (SOC)– the randomized PEPDar Study; Boston, USA. 2014. [18 November 2014]. Abstract 948. http://www​.croiconference​.org/sites/all/abstracts/948.pdf.
    47.
    Loutfy MR, Macdonald S, Myhr T, Husson H, Du Mont J, Balla S, et al. Prospective cohort study of HIV post-exposure prophylaxis for sexual assault survivors. Antivir Ther. 2007;13:87–95. [PubMed: 18389902]
    48.
    Mayer KH, Mimiaga MJ, Gelman M, Grasso C. Raltegravir, Tenofovir DF, and emtricitabine for postexposure prophylaxis to prevent the sexual transmission of HIV: safety, tolerability, and adherence. J Acquir Immune Defic Syndr. 2012;59:354–9. [PubMed: 22267017]
    49.
    Rabaud C, Bevilacqua S, Beguinot I, Dorvaux V, Schuhmacher H, May T, et al. Tolerability of postexposure prophylaxis with zidovudine, lamivudine, and nelfinavir for human immunodeficiency virus infection. Clin Infect Dis. 2001;32:1494–5. [PubMed: 11317252]
    50.
    Sonder GJB, Prins JM, Regez RM, Brinkman K, Mulder JW, Veenstra J, et al. Comparison of two HIV postexposure prophylaxis regimens among men who have sex with men in Amsterdam: adverse effects do not influence compliance. Sex Transm Dis. 2010;37:681–6. [PubMed: 20644499]
    51.
    Tan DH, Goddey-Erikefe B, Yoong D. Selecting an antiretroviral regimen for human immunodeficiency virus postexposure prophylaxis in the occupational setting. Infect Control Hosp Epidemiol Off J Soc Hosp Epidemiol Am. 2014;35:326–8. [PubMed: 24521604]
    52.
    Tosini W, Muller P, Prazuck T, Benabdelmoumen G, Peyrouse E, Christian B, et al. Tolerability of HIV postexposure prophylaxis with tenofovir/emtricitabine and lopinavir/ritonavir tablet formulation. AIDS Lond Engl. 2010;24:2375–80. [PubMed: 20729709]
    53.
    Nuesch R, Ananworanich J, Srasuebkul P. Interruptions of tenofovir/emtricitabine-based antiretroviral therapy in patients with HIV/hepatitis B virus co-infection. AIDS. 2008;22:152–4. [PubMed: 18090405]
    54.
    Dore GJ, Soriano V, Rockstroh J, Kupfer B, Tedaldi E, Peters L, et al. Frequent hepatitis B virus rebound among HIV–hepatitis B virus–coinfected patients following antiretroviral therapy interruption. AIDS. 2010;24:857–65. [PMC free article: PMC2881334] [PubMed: 20216301]
    55.
    United States Centers for Disease Control and Prevention. Serious adverse events attributed to nevirapine regimens for postexposure prophylaxis after HIV exposures worldwide, 1997–2000. MMWR Morb Mortal Wkly Rep. 2001;49:1153–6. [PubMed: 11198946]
    56.
    Patel SM, Johnson S, Belknap SM, Chan J, Beverly ES, Bennett C. Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr. 2004;35(2):120–5. [PubMed: 14722442]
    57.
    Papenburg J, Blais D, Moore D, Al-Hosni M, Laferriere C, Tapiero B, et al. Pediatric injuries from needles discarded in the community: epidemiology and risk of seroconversion. Pediatrics. 2008;122:e487–92. [PubMed: 18676535]
    58.
    Ellis JC. Introduction of HIV post-exposure prophylaxis for sexually abused children in Malawi. Arch Dis Child. 2005;90:1297–9. [PMC free article: PMC1720206] [PubMed: 16174638]
    59.
    De Waal N, Rabie H, Bester R, Cotton MF. Mass needle stick injury in children from the Western Cape. J Trop Pediatr. 2006;52:192–6. [PubMed: 16291833]
    60.
    Paediatric European Network for Treatment of AIDS (PENTA). Comparison of dual nucleoside-analogue reverse-transcriptase inhibitor regimens with and without nelfinavir in children with HIV-1 who have not previously been treated: the PENTA 5 randomised trial. Lancet. 2002;359:733–40. [PubMed: 11888583]
    61.
    Penazzato M, Prendergast A, Tierney J, Cotton M, Gibb D. Effectiveness of antiretroviral therapy in HIV-infected children under 2 years of age. Cochrane Database Syst Rev. 2012;(7) CD004772. [PubMed: 22786492]
    62.
    The PENPACT-1 (PENTA 9/PACTG 390) Study team. First-line antiretroviral therapy with a protease inhibitor versus non-nucleoside reverse transcriptase inhibitor and switch at higher versus low viral load in HIV-infected children: an open-label, randomised phase 2/3 trial. Lancet Infect Dis. 2011;11:273–83. [PMC free article: PMC3111069] [PubMed: 21288774]
    63.
    Ziske J, Kunz A, Sewangi J, Lau I, Dugange F, Hauser A, et al. Hematological changes in women and infants exposed to an AZT-containing regimen for prevention of mother-to-child-transmission of HIV in Tanzania. PLoS ONE. 2013;8:e55633. [PMC free article: PMC3566062] [PubMed: 23405185]
    64.
    Team AT, et al. Routine versus clinically driven laboratory monitoring and first-line antiretroviral therapy strategies in African children with HIV (ARROW): a 5-year open-label randomised factorial trial. Lancet. 2013;381:1391. [PMC free article: PMC3641608] [PubMed: 23473847]
    65.
    United States Centers for Disease Control and Prevention. Antiretroviral postexposure prophylaxis after sexual, injection-drug use, or other nonoccupational exposure to HIV in the United States recommendations from the U.S. Department of Health and Human Services. MMWR Morb Mortal Wkly Rep. 2005;54:1–20. [PubMed: 15660015]
    66.
    Ford N, Irvine C, Doherty M, Vitoria M, Baggaley R, Shubber Z. Do starter packs improve outcomes for people taking HIV post-exposure prophylaxis?; Poster presentation TUPE155. 20th Interantional AIDS Conference; Melbourne, Australia. 20–25 July 2014; [18 November 2014]. http://www​.aids2014.org​/webcontent/file/pag​/Posters/Tuesday/Tuesday.pdf.
    67.
    Chaiyachati KH, Ogbuoji O, Price M, Suthar AB, Negussie EK, Bärnighausen T. Interventions to improve adherence to antiretroviral therapy: a rapid systematic review. AIDS. 2014;28(Suppl 2):S187–204. [PubMed: 24849479]
    68.
    Bentz L, Enel P, Dunais B, Durant J, Poizot-Martin I, Tourette-Turgis C, et al. Evaluating counseling outcome on adherence to prophylaxis and follow-up after sexual HIV-risk exposure: a randomized controlled trial. AIDS Care. 2010;22:1509–16. [PubMed: 20824548]
    69.
    Rueda S, Park-Wyllie LY, Bayoumi A, Tynan AM, Antoniou T, Rourke S, et al. Patient support and education for promoting adherence to highly active antiretroviral therapy for HIV/AIDS. Cochrane Database Syst Rev. 2006;(3) CD001442. [PMC free article: PMC7045748] [PubMed: 16855968]
    70.
    Chung MH, Richardson BA, Tapia K, Benki-Nugent S, Kiarie JN, Simoni JM, et al. A randomized controlled trial comparing the effects of counseling and alarm device on HAART adherence and virologic outcomes. PLoS Med. 2011;8:e1000422. [PMC free article: PMC3046986] [PubMed: 21390262]
    71.
    Hepatitis B. Geneva: World Health Organization; 2014. [18 November 2014]. http://www​.who.int/csr​/disease/hepatitis​/HepatitisB_whocdscsrlyo2002_2.pdf?ua=1.
    72.
    Guidelines for the screening, care and treatment of persons with hepatitis C infection. Geneva: World Health Organization; 2014. [18 November 2014]. http://www​.who.int/hiv​/pub/hepatitis/hepatitis-c-guidelines​/en. [PubMed: 25535634]
    73.
    Guidelines for the management of sexually transmitted infections. Geneva: World Health Organization; 2003. [18 November 2014]. http://search​.ebscohost​.com/login.aspx?direct​=true&scope​=site&db​=nlebk&db=nlabk&AN​=113199.
    74.
    Essential medicines for reproductive health: guiding principles for their inclusion on national medicine lists. Geneva: World Health Organization; 2006.
    75.
    Standards for maternal and neonatal care: Integrated Management of Pregnancy and Childbirth (IMPAC) prevention and management of sexually transmitted and reproductive tract infections. Geneva: World Health Organization; 2006. [18 November 2014]. http://www​.who.int/reproductivehealth​/publications​/maternal_perinatal_health​/prevention_mngt_stis​.pdf.
    76.
    Tetanus. Manila: WHO Office for the Western Pacific; 2012. [18 November 2014]. http://www​.wpro.who.int​/mediacentre/factsheets​/fs_20120307_tetanus/en.
    77.
    Delivering HIV test results and messages for re-testing and counselling in adults. Geneva: World Health Organization; 2010. [18 November 2014]. http://www​.who.int/hiv​/pub/vct/hiv_re_testing/en. [PubMed: 26269878]
    78.
    Consolidated guidelines on HIV prevention, diagnosis, treatment and care for key populations. Geneva: World Health Organization; 2014. [18 November 2014]. http://apps​.who.int/iris​/bitstream/10665​/128048/1/9789241507431_eng​.pdf?ua=1&ua=1. [PubMed: 25996019]
    79.
    Recommendation concerning HIV and AIDS and the world of work (no. 200). Geneva: International Labour Office; 2010. [18 November 2014]. http://www​.ilo.org/wcmsp5​/groups/public/---ed_protect​/---protrav​/---ilo_aids/documents​/normativeinstrument/wcms_142706​.pdf.
    80.
    WHO and ILO. Joint WHO/ILO policy guidelines on improving health worker access to prevention, treatment and care services for HIV and TB. Geneva: World Health Organization; 2010. [18 November 2014]. http://apps​.who.int/iris​/handle/10665/44467. [PubMed: 26180899]
    81.
    Responding to intimate partner violence and sexual violence against women: WHO clinical and policy guidelines. Geneva: World Health Organization; 2013. [18 November 2014]. https://extranet​.who​.int/iris/restricted/handle/10665/85240. [PubMed: 24354041]
    82.
    March 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2014. [18 November 2014]. http://apps​.who.int/iris​/handle/10665/104264.
    83.
    HIV and adolescents: guidance for HIV testing and counselling and care for adolescents living with HIV: recommendations for a public health approach and considerations for policy-makers and managers. Geneva: World Health Organization; 2013. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/adolescents/en. [PubMed: 25032477]

    SECTION 5. THE USE OF CO-TRIMOXAZOLE PROPHYLAXIS FOR HIV-RELATED INFECTIONS AMONG ADULTS, ADOLESCENTS AND CHILDREN

    1.
    WHO expert consultation on co-trimoxazole prophylaxis in HIV infection. Geneva: World Health Organization; 2006. [18 November 2014]. http://www​.who.int/hiv​/pub/meetingreports​/ctxprophylaxismeeting.pdf.
    2.
    Guidelines on co-trimoxazole prophylaxis for HIV related infections among children, adolescents and adults: recommendations for a public health approach. Geneva: World Health Organization; 2006. [PubMed: 26042326]
    3.
    Alemu AW, Sebastián MS. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromiyaa, Ethiopia. Glob Health Action. 2010;3 [PMC free article: PMC2967337] [PubMed: 21042435]
    4.
    Amuron B, Levin J, Birunghi J, Namara G, Coutinho A, Grosskurth H, et al. Mortality in an antiretroviral therapy programme in Jinja, south-east Uganda: a prospective cohort study. AIDS Res Ther. 2011;8:39. [PMC free article: PMC3210087] [PubMed: 22018282]
    5.
    Auld AF, Mbofana F, Shiraishi RW, Sanchez M, Alfredo C, Nelson LJ, et al. Four-year treatment outcomes of adult patients enrolled in Mozambique's rapidly expanding antiretroviral therapy program. PLoS One. 2011;6:e18453. [PMC free article: PMC3070740] [PubMed: 21483703]
    6.
    Hoffmann CJ, Fielding KL, Charalambous S, Innes C, Chaisson RE, Grant AD, et al. Reducing mortality with co-trimoxazole preventive therapy at initiation of antiretroviral therapy in South Africa. AIDS. 2010;24:1709–16. [PMC free article: PMC2956913] [PubMed: 20495439]
    7.
    Lim PL, Zhou J, Ditangco RA, Law MG, Sirisanthana T, Kumarasamy N, et al. Failure to prescribe Pneumocystis prophylaxis is associated with increased mortality, even in the cART era: results from the Treat Asia HIV observational database. J Int AIDS Soc. 2012;15:1. [PMC free article: PMC3354658] [PubMed: 22281054]
    8.
    Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, Eiger O, et al. Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering co-trimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr. 2007;46:56–61. [PubMed: 17972365]
    9.
    Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, et al. Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia. AIDS. 2007;21:351–9. [PubMed: 17255742]
    10.
    van Oosterhout JJ, Ndekha M, Moore E, Kumwenda JJ, Zijlstra EE, Manary M. The benefit of supplementary feeding for wasted Malawian adults initiating ART. AIDS Care. 2010;22:737–42. [PubMed: 20467944]
    11.
    Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, Reid A, et al. Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet. 2010;375:1278–86. [PMC free article: PMC2858802] [PubMed: 20347483]
    12.
    Anglaret X, Chêne G, Attia A, Toure S, Lafont S, Combe P, et al. Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial. Cotrimo-CI Study Group. Lancet. 1999;353:1463–8. [PubMed: 10232311]
    13.
    Mermin J 1, Lule J, Ekwaru JP, Malamba S, Downing R, Ransom R, et al. Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet. 2004;364:1428–34. [PubMed: 15488218]
    14.
    Ouiminga M, Eholié SP, Ouattara IS, Denoeud L, Adjé TC, Ello F, et al. Incidence of malarial episodes in a cohort of west African HIV-1 infected adults exposed or not to co-trimoxazole chemoprophylaxis. MALHIV Study. Submitted.
    15.
    Watera C, Todd J, Muwonge R, Whitworth J, Nakiyingi-Miiro J, Brink A, et al. Feasibility and effectiveness of co-trimoxazole prophylaxis for HIV-1-infected adults attending an HIV/AIDS clinic in Uganda. J Acquir Immune Defic Syndr. 2006;42:373–8. [PubMed: 16810124]
    16.
    Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, Muramuzi E, et al. HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/μL who discontinue co-trimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis. 2012;54:1204–11. [PubMed: 22423133]
    17.
    Polyak CS, Yuhas K, Singa B, Khaemba M, Watson J, Richardson B, et al. CTX prophylaxis discontinuation among ART-treated adults: a randomized non-inferiority trial. CROI. 2014. Abstract 98.
    18.
    Chaiwarith R, Praparattanapan J, Nuntachit N, Kotarathitithum W, Supparatpinyo K. Discontinuation of primary and secondary prophylaxis for opportunistic infections in HIV-infected patients who had CD4+ cell count <200 cells/mm3 but undetectable plasma HIV-1 RNA: an open-label randomized controlled trial. AIDS Patient Care STDs. 2013;27:71–6. [PubMed: 23373662]
    19.
    Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, Morlat P, et al. Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/μL? Clin Infect Dis. 2010;51:611–9. [PubMed: 20645862]
    20.
    Guidelines Version 7.0. Brussels: European AIDS Clinical Society; 2013. [18 November 2014]. http://www​.eacsociety​.org/Portals/0/Guidelines​_Online_131014.pdf.
    21.
    Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. Atlanta: Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents; 2014. [18 November 2014]. http://aidsinfo​.nih.gov​/contentfiles/lvguidelines/adult_oi​.pdf. [PubMed: 19357635]
    22.
    Forna F, McConnell M, Kitabire FN, Homsy J, Brooks JT, et al. Systematic review of the safety of trimethoprim-sulfamethoxazole for prophylaxis in HIV-infected pregnant women: implications for resource-limited settings. AIDS Rev. 2006;8:24–36. [PubMed: 16736949]
    23.
    Prevention of neural tube defects: integrated management of pregnancy and childbirth. Geneva: World Health Organization; 2002. [18 November 2014]. http://www​.who.int/reproductivehealth​/publications​/maternal_perinatal_health​/neural_tube_defects.pdf.
    24.
    Ford N 1, Shubber Z, Jao J, Abrams EJ, Frigati L, Mofenson L. Safety of cotrimoxazole in pregnancy: a systematic review and meta-analysis. J Acquir Immune Defic Syndr. 2014;66:512–21. [PMC free article: PMC4331013] [PubMed: 24853309]
    25.
    Updated WHO policy recommendation: intermittent preventive treatment of malaria in pregnancy using sulfadoxine-pyrimethamine (IPTp-SP) October 2012. Geneva: World Health Organization; 2012. [18 November 2014]. http://www​.who.int/malaria​/publications/atoz​/who_iptp_sp_policy_recommendation​/en.
    26.
    Klement E, Pitché P, Kendjo E, Singo A, D'Almeida S, Akouete F, et al. Effectiveness of co-trimoxazole to prevent Plasmodium falciparum malaria in HIV-positive pregnant women in sub-Saharan Africa: an open-label, randomized controlled trial. Clin Infect Dis. 2014;58:651–9. [PubMed: 24336820]
    27.
    Denoeud-Ndam L, Zannou DM, Fourcade C, Taron-Brocard C, Porcher R, Atadokpede F, et al. Co-trimoxazole prophylaxis versus mefloquine intermittent preventive treatment to prevent malaria in HIV-infected pregnant women: two randomized controlled trials. J Acquir Immune Defic Syndr. 2014;65:198–206. [PubMed: 24220287]
    28.
    Boeree MJ, Sauvageot D, Banda HT, Harries AD, Zijlstra EE. Efficacy and safety of two dosages of co-trimoxazole as preventive treatment for HIV-infected Malawian adults with new smear-positive tuberculosis. Trop Med Int Health. 2005;10:723–33. [PubMed: 16045458]
    29.
    Schneider MM, Nielsen TL, Nelsing S, Hoepelman AI, Eeftinck Schattenkerk JK, van der Graaf Y, et al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus. Dutch AIDS Treatment Group. J Infect Dis. 1995;171:1632–6. [PubMed: 7769306]
    30.
    Chintu C, et al. Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomised placebo-controlled trial. Lancet. 2004;364:1865–71. [PubMed: 15555666]
    31.
    Grimwade K, Swingler GH. Co-trimoxazole prophylaxis for opportunistic infections in children with HIV infection. Cochrane Database Syst Rev. 2006;1 CD003508. [PMC free article: PMC7046007] [PubMed: 16437457]
    32.
    Ryan M, et al. The cost-effectiveness of co-trimoxazole prophylaxis in HIV-infected children in Zambia. AIDS. 2008;22:749–57. [PubMed: 18356605]
    33.
    Prendergast A, Walker AS, Mulenga V, et al. Improved growth and anemia in HIV-infected African children taking cotrimoxazole prophylaxis. Clin Infect Dis. 2011;52:953–6. [PubMed: 21427404]
    34.
    Walker AS, et al. The impact of daily co-trimoxazole prophylaxis and antiretroviral therapy on mortality and hospital admissions in HIV-infected Zambian children. Clin Infect Dis. 2007;44:1361–7. [PubMed: 17443476]
    35.
    Mulenga V, et al. Effect of co-trimoxazole on causes of death, hospital admissions and antibiotic use in HIV-infected children. AIDS. 2007;21:77–84. [PubMed: 17148971]
    36.
    Bwakura-Dangarembizi M, et al. A randomized trial of stopping or continuing co-trimoxazole in HIV-infected children. N Engl J Med. 2014;370:41–53. [PMC free article: PMC4264559] [PubMed: 24382064]
    37.
    Nachman S, et al. The rate of serious bacterial infections among HIV-infected children with immune reconstitution who have discontinued opportunistic infection prophylaxis. Pediatrics. 2005;115:e488–94. [PubMed: 15772172]
    38.
    Urschel S, et al. European PCP-withdrawal Study Group. Withdrawal of Pneumocystis jirovecii prophylaxis in HIV-infected children under highly active antiretroviral therapy. AIDS. 2005;19:2103–8. [PubMed: 16284459]
    39.
    Panel on Antiretroviral Therapy and Medical Management of HIV-Infected Children Guidelines for the Use of Antiretroviral Agents in Pediatric HIV Infection. Bethesda (MD): National Institutes of Health; 2014. [18 November 2014]. http://aidsinfo​.nih.gov​/contentfiles/lvguidelines​/pediatricguidelines.pdf. [PubMed: 11590506]
    40.
    Bamford A, Turkova A, Lyall H, Foster C, Klein N, Bastiaans D, et al. for the PENTA steering committee. PENTA guidelines for treatment of paediatric HIV-1 infection 2014: optimising health in preparation for adult life. HIV Med. In press. [PMC free article: PMC5724658] [PubMed: 25649230]
    41.
    Fisher RG, et al. Successful prophylaxis against Pneumocystis carinii pneumonia in HIV-infected children using smaller than recommended dosages of trimethoprim-sulfamethoxazole. AIDS Patient Care STDs. 2001;15:263–9. [PubMed: 11530767]
    42.
    Coutsoudis A, Kindra G, Esterhuizen T. Impact of co-trimoxazole prophylaxis on the health of breast-fed, HIV-exposed, HIV-negative infants in a resource-limited setting. AIDS. 2011;25:1797–9. [PubMed: 21785320]
    43.
    Landes M, et al. Mortality and health outcomes of HIV exposed and unexposed children in a PMTCT cohort in Malawi. PLoS ONE. 2012;7:e47337. [PMC free article: PMC3474798] [PubMed: 23082157]
    44.
    Sandison TG, et al. Protective efficacy of co-trimoxazole prophylaxis against malaria in HIV exposed children in rural Uganda: a randomised clinical trial. BMJ. 2011;342:d1617. [PMC free article: PMC3068910] [PubMed: 21454456]
    45.
    Thyagarajan B, Deshpande SS. Co-trimoxazole and neonatal kernicterus: a review. Drug Chem Toxicol. 2014;37:121–9. [PMC free article: PMC4105183] [PubMed: 24099411]
    46.
    Rozin A, Schapira D, Braun-Moscovici Y, Nahir AM. Co-trimoxazole treatment for rheumatoid arthritis. Semin Arthritis Rheum. 2001;31:133–41. [PubMed: 11590583]
    47.
    Consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: recommendations for a public health approach. Geneva: World Health Organization; 2013. [18 November 2014]. http://www​.who.int/hiv​/pub/guidelines/arv2013/download/en. [PubMed: 24716260]
    48.
    Under-five mortality. Geneva: World Health Organization; 2014. [18 November 2014]. http://www​.who.int/gho​/child_health/mortality​/mortality_under_five/en.
    49.
    WHO policy on collaborative TB/HIV policy activities: guidelines for national programmes and other stakeholders. Geneva: World Health Organization; 2012. [PubMed: 23586124]
Copyright © World Health Organization 2014.

All rights reserved. Publications of the World Health Organization are available on the WHO website (www.who.int) or can be purchased from WHO Press, World Health Organization, 20 Avenue Appia, 1211 Geneva 27, Switzerland (tel.: +41 22 791 3264; fax: +41 22 791 4857; e-mail: tni.ohw@sredrokoob).

Requests for permission to reproduce or translate WHO publications –whether for sale or for non-commercial distribution– should be addressed to WHO Press through the WHO website (www.who.int/about/licensing/copyright_form/en/index.html).

Bookshelf ID: NBK298971
Contents

Views

  • PubReader
  • Print View
  • Cite this Page
  • PDF version of this title (2.5M)

Other titles in this collection

Recent Activity

ClearTurn OffTurn On

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...